Covovax nod to strengthen immunization efforts in India: SII

Published On 2021-12-31 05:00 GMT   |   Update On 2021-12-31 10:24 GMT

Vaccine major serum institute of India (SII) on Tuesday said the approval for the covid-19 vaccine 'covovax' would strength immunization across India and various lower and middle income countries (LMIC's) across the world."The approval of Covovax by DCGI is a significant milestone in strengthening our immunization efforts across india and LMIC's. We are proud to deliver a...

Login or Register to read the full article

Vaccine major serum institute of India (SII) on Tuesday said the approval for the covid-19 vaccine 'covovax' would strength immunization across India and various lower and middle income countries (LMIC's) across the world.

"The approval of Covovax by DCGI is a significant milestone in strengthening our immunization efforts across india and LMIC's. We are proud to deliver a highly-effective protein-based COVID-19 vaccine of more than 90 per dent efficacy rate, based on clinical data demonstrating a favorable safty profile. we are certain that as the repertoire of the COVID-19 vaccine increases, we will be poised strongly to save the lives of millions of people against the pandemic, " SII CEO adar poonawalla said the the statement. 

For more details, check out the full story on the link  below:

Immunization Efforts IN India, Lower, Middle Income Countries To Strengthen With Covovax Approval, Say SII 

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News